Evaluating the efficacy of neoadjuvant endocrine therapy in HER2 low vs. HER2 negative breast cancer: An NCBD analysis

被引：0
|
作者：
Chong, Esther G.
Guo, Mengni
Castillo, Dani Ran
Bazan, Jose G.
Yap, Kelly Khai Li
Schultz-Costello, Katharine
Wu, S. Peter
机构：
[1] Loma Linda Univ, Dept Oncol Hematol, Med Ctr, Loma Linda, CA USA
[2] City Hope Natl Canc Ctr, Duarte, CA USA
[3] City Hope Natl Med Ctr, Duarte, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
599
引用
收藏
页数：1
相关论文
共 50 条
  • [31] HER2 as a target for breast cancer therapy
    Tagliabue, Elda
    Balsari, Andrea
    Campiglio, Manuela
    Pupa, Serenella M.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (05) : 711 - 724
  • [32] The Survival Benefit of Endocrine Therapy in Low Estrogen Receptor Positive/HER2 Negative Invasive Breast Cancer
    Alhamar, Mohamed
    Alkamachi, Bassam
    Mehrotra, Harshita
    Ohan, Hovsep
    Ali, Haythem
    Gupta, Nilesh
    Hassan, Oudai
    Chitale, Dhananjay
    Schultz, Daniel
    Allo, Ghassan
    Alkhoory, Wamidh
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 74 - 76
  • [33] The Survival Benefit of Endocrine Therapy in Low Estrogen Receptor Positive/HER2 Negative Invasive Breast Cancer
    Alhamar, Mohamed
    Alkamachi, Bassam
    Mehrotra, Harshita
    Ohan, Hovsep
    Ali, Haythem
    Gupta, Nilesh
    Hassan, Oudai
    Chitale, Dhananjay
    Schultz, Daniel
    Allo, Ghassan
    Alkhoory, Wamidh
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 74 - 76
  • [34] Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
    Laidi, Fatna
    Bouziane, Amal
    Lakhdar, Amina
    Khabouze, Samira
    Rhrab, Brahim
    Zaoui, Fatima
    ONCOTARGETS AND THERAPY, 2014, 7 : 1285 - 1289
  • [35] Loss of HER2 amplification and disease prognosis after neoadjuvant treatment of HER2 amplified breast cancer
    Paralta Branco, F.
    Silva, F.
    Andre, S.
    Catarino, A.
    Madureira, R.
    Moreira Pinto, J.
    Godinho, J.
    Simoes, P.
    Freitas, A. C.
    Casa-Nova, M.
    Nave, M.
    Augusto, J.
    Passos-Coelho, J. L.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S94 - S94
  • [36] Reassessment of HER2 status in breast cancer patients with initially HER2 negative or HER2 unknown primary tumors at the time of metastatic disease by serum HER2 and HER2 status of circulating tumor cells
    Fehm, T.
    Solomayer, E.
    Uhr, J.
    Wallwiener, D.
    ONKOLOGIE, 2008, 31 : 51 - 51
  • [37] Evaluating Low HER2 Status in Invasive Breast Carcinoma via HER2 Immunohistochemistry, with HER2 FISH Correlation: A Cohort of 112 Patients
    Ardor, Gokce Deniz
    Komforti, Miglena K.
    Hanna, Helena
    Ibanoglu, Onur
    Lochala, Abigail
    Nassar, Aziza
    BREAST JOURNAL, 2023, 2023
  • [38] Evaluating HER2 amplification and overexpression in breast cancer
    Bartlett, JMS
    Going, JJ
    Mallon, EA
    Watters, AD
    Reeves, JR
    Stanton, P
    Richmond, J
    Donald, B
    Ferrier, R
    Cooke, TG
    JOURNAL OF PATHOLOGY, 2001, 195 (04): : 422 - 428
  • [39] PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2 positive metastatic breast cancer
    Metzger-Filho, Otto
    Mandrekar, Sumithra
    Loibl, Sibylle
    Ciruelos, Eva
    Gianni, Luca
    Lim, Elgene
    Miller, Kathy
    Huang, Cynthia
    Koehler, Maria
    Francis, Prue
    Valagussa, Pinuccia
    Goel, Shom
    Prat, Aleix
    Goetz, Matthew
    Loi, Sherene
    Krop, Ian
    Carey, Lisa
    Lanzillotti, Jane
    Winer, Eric
    Tripathy, Debu
    DeMichele, Angela
    CANCER RESEARCH, 2018, 78 (04)
  • [40] HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer
    Hou, Yanjun
    Nitta, Hiroaki
    Li, Zaibo
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2017, 147 (01) : 89 - 95
12345